Antibody therapy for chronic lymphocytic leukemia

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Monoclonal antibodies targeting CD20 and CD52 have transformed chronic lymphocytic leukemia (CLL) therapy.
• Rituximab is integrated into chemoimmunotherapy for previously untreated patients, while alemtuzumab is used less frequently due to toxicity concerns.

Purpose of the Study:

• To review the current role and emerging applications of monoclonal antibodies in CLL treatment.
• To discuss the efficacy, toxicity, and future directions of anti-CD20 and anti-CD52 therapies, including investigational agents.

Main Methods:

• Review of clinical trial data and published literature on rituximab and alemtuzumab in CLL.
• Analysis of efficacy, safety profiles, and mechanisms of action for key monoclonal antibodies.

Main Results:

• Rituximab combined with chemotherapy improves complete response rates and progression-free survival in CLL, but long-term survival benefit is not yet established.
• Alemtuzumab, despite toxicity concerns, demonstrates activity in relapsed CLL, particularly with del(17p13), and potential for minimal residual disease (MRD) eradication.
• Subcutaneous alemtuzumab reduces infusion toxicity but carries risks of hematologic complications and infections like CMV reactivation.

Conclusions:

• Monoclonal antibodies are integral to modern CLL management, offering improved response rates and MRD eradication potential.
• Ongoing research focuses on optimizing antibody-based therapies, including novel agents and consolidation strategies to enhance long-term outcomes in CLL.
• Careful patient selection and toxicity monitoring are crucial for maximizing the benefits of these targeted therapies in chronic lymphocytic leukemia.